Merck CEO Rob Davis said the drugmaker has evolved beyond Keytruda, with more than 20 potential blockbuster launches over the next five years.
Read full articleMerck CEO says new pipeline is built to offset Keytruda's eventual patent expiration
Written on 08/05/2026